Form 4: C4 Therapeutics Director Steven L. Hoerter Acquires 65,000 Stock Options

Steven L. Hoerter, a director at C4 Therapeutics, acquired 65,000 stock options on November 19, 2024, which vest over time.

Summary

• Steven L. Hoerter, a director of C4 Therapeutics, acquired 65,000 stock options on November 19, 2024.
• The exercise price of these options is $4.15 per share.
• The options vest over time, with 33% vesting on November 19, 2025, and the remainder vesting in eight equal quarterly installments thereafter.
• The vesting is contingent upon Mr. Hoerter's continued service with the company.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally a positive sign, indicating confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The vesting schedule of the options suggests a long-term commitment from the director.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice across the biotechnology industry, similar to companies like Amgen, Gilead, and Biogen.
• The vesting schedule is typical, with a portion vesting after one year and the remainder vesting over several years, aligning with industry norms for long-term incentives.

Stakeholder Impact

• The stock option grant could positively impact shareholder sentiment by demonstrating director alignment with company performance.

Key Dates

Keywords

stock options, insider trading, director, C4 Therapeutics, equity, vesting